Skip to main content
. 2021 Jun 30;13(7):995. doi: 10.3390/pharmaceutics13070995

Figure 4.

Figure 4

(a) Cell migration rates of Raw264.7 cells to 4T1 cells treated with MA@Fe3O4/Au DSNFs with 4T1 cell-guided, MA with 4T1 cell-guided, MA@Fe3O4/Au DSNFs without 4T1 cell-guided, and MA without 4T1 cell-guided for 18 h. (b) Quantification of CD80 and CD206 expression via flow cytometry for Raw264.7 cells incubating with and without Fe3O4/Au DSNFs in the in vitro experiment.